Current periprocedural anticoagulation in transcatheter aortic valve replacement: could bivalirudin be an option? Rationale and design of the BRAVO 2/3 studies.
about
Challenges in cardiac device innovation: is neuroimaging an appropriate endpoint? Consensus from the 2013 Yale-UCL Cardiac Device Innovation Summit.Transcatheter aortic valve insertion (TAVI): a review.Antithrombotic therapy before, during and after transcatheter aortic valve replacement (TAVR).Stroke after transcatheter aortic valve replacement: incidence, risk factors, prognosis, and preventive strategies.
P2860
Current periprocedural anticoagulation in transcatheter aortic valve replacement: could bivalirudin be an option? Rationale and design of the BRAVO 2/3 studies.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Current periprocedural anticoa ...... sign of the BRAVO 2/3 studies.
@en
type
label
Current periprocedural anticoa ...... sign of the BRAVO 2/3 studies.
@en
prefLabel
Current periprocedural anticoa ...... sign of the BRAVO 2/3 studies.
@en
P2093
P2860
P50
P1476
Current periprocedural anticoa ...... sign of the BRAVO 2/3 studies.
@en
P2093
Eberhard Grube
Efthymios N Deliargyris
Jochen Reinöhl
Socrates Kakoulides
Thierry Lefèvre
Usman Baber
Ziad Sergie
P2860
P2888
P304
P356
10.1007/S11239-013-0890-3
P577
2013-05-01T00:00:00Z